Shattuck Labs (NASDAQ:STTK) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Shattuck Labs (NASDAQ:STTK) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $28.00 price target on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and set a $12.00 price target on shares of Shattuck Labs in a report on Tuesday, April 9th.

Shattuck Labs Stock Down 2.9 %

Shares of Shattuck Labs stock traded down $0.32 during trading hours on Thursday, hitting $10.78. The company’s stock had a trading volume of 255,663 shares, compared to its average volume of 294,183. Shattuck Labs has a 1-year low of $1.33 and a 1-year high of $11.62. The business has a fifty day moving average of $9.42 and a 200 day moving average of $6.95. The company has a market capitalization of $512.59 million, a PE ratio of -5.59 and a beta of 1.98.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.08. Shattuck Labs had a negative net margin of 3,133.63% and a negative return on equity of 64.46%. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $0.30 million. The business’s revenue was up 2200.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Shattuck Labs will post -1.85 earnings per share for the current fiscal year.

Insider Activity at Shattuck Labs

In related news, insider Stephen Stout sold 16,004 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total transaction of $168,522.12. Following the completion of the sale, the insider now directly owns 74,437 shares of the company’s stock, valued at approximately $783,821.61. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 9.89% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its stake in Shattuck Labs by 79.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after acquiring an additional 5,989 shares during the last quarter. SG Americas Securities LLC bought a new position in Shattuck Labs during the 4th quarter valued at $268,000. Reliant Investment Management LLC bought a new position in Shattuck Labs during the 4th quarter valued at $143,000. Cannon Global Investment Management LLC bought a new position in Shattuck Labs during the 1st quarter valued at $91,000. Finally, Pinnacle Associates Ltd. boosted its stake in Shattuck Labs by 13.9% during the 1st quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock valued at $4,660,000 after acquiring an additional 63,800 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.